MedTrace Logo

Sunphenon in Progressive Forms of Multiple Sclerosis

NCT00799890 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2021-07-29

No results posted yet for this study

Summary

The investigators hypothesize that an oral Sunphenon EGCg (Epigallocatechin-Gallat, EGCG) treatment is - due to its antiinflamatoric and neuroprotective potence - significantly more effective than an oral placebo treatment regarding following parameters: increase in brain atrophy, number of new T2-lesions in the cerebral magnetic resonance tomography, reduction of the NAA/Cr-ratio in MR-spectroscopy, progression of disability such as cognitive disorders in patients with MS.

Conditions

Interventions

DRUG

Sunphenon EGCG

200-800mg (1-4 capsules)

DRUG

Placebo

1-4 capsules

Sponsors & Collaborators

  • TAIYO EUROPE

    collaborator UNKNOWN

  • Friedemann Paul

    lead OTHER

Principal Investigators

  • Friedemann Paul, Dr. · Charite University (NeuroCure Clinical Research Center)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2016-03-31
Completion
2016-03-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00799890 on ClinicalTrials.gov